358 patents
Page 6 of 18
Utility
Modulators of IRF4 Expression
4 Aug 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Tianyuan ZHOU, Youngsoo KIM, Robert MACLEOD, Huynh-Hoa BUI, Susan M. FREIER
Filed: 17 Dec 21
Utility
Compositions and Methods for Modulating Tau Expression
4 Aug 22
Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds.
Frank Rigo
Filed: 22 Sep 21
Utility
Compounds and Methods for Reducing Fus Expression
4 Aug 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FUS RNA in a cell or subject, and in certain instances reducing the amount of FUS protein in a cell or subject.
Huynh-Hoa Bui
Filed: 28 May 20
Utility
Modulators of MALAT1 Expression
4 Aug 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
Susan M. FREIER, Youngsoo KIM, Robert MACLEOD
Filed: 8 Feb 22
Utility
Modulators of Complement Factor B
4 Aug 22
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
Filed: 2 Sep 21
Utility
Angiotensin II Type 1 Receptor Targeted Oligonucleotides and Uses Thereof
4 Aug 22
The present disclosure provides compounds and methods for targeting cells expressing AGTR1.
Adam Mullick, Yichun Kuo, Ting Yuan Yeh, Thazha P. Prakash
Filed: 18 May 20
Utility
Method of conjugating oligomeric compounds
2 Aug 22
Provided herein are solid phase methods for the synthesis of conjugated oligomeric compounds and intermediates used in such methods.
Isaiah E. Cedillo, Recaldo Carty
Filed: 6 Oct 17
Utility
Compositions and Methods for Modulating MECP2 Expression
21 Jul 22
Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression.
Susan M. Freier
Filed: 23 Aug 21
Utility
Modulation of factor 11 expression
5 Jul 22
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof.
Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
Filed: 29 Jul 20
Utility
Compositions for Modulating Ataxin 2 Expression
23 Jun 22
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression.
Susan M. Freier
Filed: 4 Aug 21
Utility
Compounds and Methods for Reducing ATXN3 Expression
23 Jun 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal.
Hien Thuy Zhao, Holly Kordasiewicz, Ruben E. Valas
Filed: 21 Feb 20
Utility
Modulators of EZH2 expression
21 Jun 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
Filed: 11 Apr 19
Utility
Linkage Modified Oligomeric Compounds and Uses Thereof
16 Jun 22
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.
Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
Filed: 15 Feb 22
Utility
Compositions and Methods for Enhanced Intestinal Absorption of Conjugated Oligomeric Compounds
16 Jun 22
The present disclosure provides compositions for enhanced intestinal absorption of oligomeric compounds.
Justin Drew Searcy, Zhengrong Yu, Julie C. Ma, Yanfeng Wang, Kaustubh H. Kulkarni
Filed: 9 Nov 21
Utility
Compounds and Methods for Reducing KCNT1 Expression
9 Jun 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject.
Huynh-Hoa Bui, Susan M. Freier
Filed: 13 Mar 20
Utility
Modulation of Prekallikrein (PKK) Expression
2 Jun 22
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression.
Susan M. Freier, Huynh-Hoa Bui
Filed: 2 Jul 21
Utility
Compositions Comprising Alternating 2'-MODIFIED Nucleosides for Use In Gene Modulation
26 May 22
The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target.
Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
Filed: 28 Jun 21
Utility
Methods for Reducing ATAXIN-2 Expression
26 May 22
Provided herein are methods for decreasing Ataxin-2 mRNA expression.
Frank Rigo
Filed: 18 May 21
Utility
Compositions for modulating C9ORF72 expression
24 May 22
Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors.
Susan M. Freier, Frank Rigo
Filed: 15 Jan 19
Utility
Compounds and methods for reducing LRRK2 expression
17 May 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least 5 one symptom or hallmark of a neurodegenerative disease.
Susan M. Freier
Filed: 27 Jun 19